Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Dumas (Le Plessis Robinson,, France), G. Bru-Mercier (Le Plessis Robinson,, France), A. Courboulin (Le Plessis Robinson,, France), M. Quatredeniers (Le Plessis Robinson,, France), C. Rucker-Martin (Le Plessis Robinson,, France), F. Antigny (Le Plessis Robinson,, France), M. Nakhleh (Le Plessis Robinson,, France), B. Ranchoux (Le Plessis Robinson,, France), E. Gouadon (Le Plessis Robinson,, France), M. Vinhas (Le Plessis Robinson,, France), M. Vocelle (Le Plessis Robinson,, France), N. Raymond (Le Plessis Robinson,, France), P. Dorfmuller (Le Plessis Robinson,, France), E. Fadel (Le Plessis Robinson,, France), F. Perros (Le Plessis Robinson,, France), M. Humbert (Le Kremlin-Bicetre, France), S. Cohen-Kaminsky (Le Plessis Robinson,, France). NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension. 3938

Member's Comments

No comment yet.

Related content which might interest you: Pharmacological activation of Nur77 enhances BMP signalling and inhibits vascular remodelling in pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 The effect of estrogen and its receptor on hypoxic pulmonary vascular remodeling Source: Eur Respir J 2006; 28: Suppl. 50, 658s Year: 2006 2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 LSC Abstract – Glutamatergic signaling through pulmonary vascular NMDA receptors in pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Effects of BMPR-II signal transduction in the pulmonary vascular remodeling of monocrotaline induced pulmonary hypertension in rats Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects Source: Eur Respir J, 50 (2) 1602337; 10.1183/13993003.02337-2016 Year: 2017 NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Pathobiology of pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 1559-1572 Year: 2002 Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1137-1149 Year: 2016 Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020 Year: 2020 Role of c-Abelson in the loss of genome integrity in endothelial cells in pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 TrkB expression is altered in hypoxia-induced pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 606s Year: 2007 Adrenergic receptor blocker reverses cardiac metabolic remodeling and improves right ventricular function in experimental pulmonary hypertension Source: Annual Congress 2011 - Molecular: pathology of infectious and inflammatory lung disease Year: 2011 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Expression of the serotonin 1b receptor in experimental pulmonary hypertension Source: Eur Respir J 2003; 22: 408-412 Year: 2003